Ocrevus Zunovo ocrelizumab 920 mg and hyaluronidase-ocsq 23,000 units /23 mL Images
Generic Name: hyaluronidase/ocrelizumab
This medication has been identified as Ocrevus Zunovo ocrelizumab 920 mg and hyaluronidase-ocsq 23,000 units /23 mL. It is supplied by Genentech, Inc.
Ocrevus Zunovo is used in the treatment of Multiple Sclerosis and belongs to the drug class CD20 monoclonal antibodies. Ocrevus Zunovo ocrelizumab 920 mg and hyaluronidase-ocsq 23,000 units /23 mL is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Ocrevus Zunovo
- Generic Name
- hyaluronidase/ocrelizumab
- Strength
- ocrelizumab 920 mg and hyaluronidase-ocsq 23,000 units /23 mL
- Availability
- Prescription only
- Drug Class
- CD20 monoclonal antibodies
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Genentech, Inc.
- National Drug Code (NDC)
- 50242-0554
More about Ocrevus Zunovo (hyaluronidase / ocrelizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD20 monoclonal antibodies
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.